it depends. Based on the past deals, the take over targets with approved drugs typically attract premium less than 100% because much of the gains has already been realised post FDA approval. For companies with mainly phase 2 or phase 3 pipelines, the premium is typically 100-200%. NEU would fall under the 2nd scenario and given the size and potential of the pipeline, I wouldn’t be surprised the premium is over 200% as the market has not yet fully appreciated the potential opportunity here
Take Over Opportunity, page-39
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.57 |
Change
-0.040(0.26%) |
Mkt cap ! $1.990B | |||
| Open | High | Low | Value | Volume |
| $15.83 | $15.87 | $15.20 | $8.124M | 524.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 64 | $15.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.58 | 597 | 1 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |